SLDB, US83422E2046

UBS initiated coverage of Solid Biosciences stock with USD 20 target

Published on 10/16/2026 at 03:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS set a USD 20.00 target on October 14, 2026. Solid Biosciences stock last stood at USD 5.74 on Nasdaq after hours on October 15, 2026.

Upcoming catalysts and cash

UBS set a USD 20.00 target on October 14, 2026.
Solid Biosciences posted a USD 54.8 million GAAP loss for the second quarter of 2026.
Q3 2026 earnings are estimated for November 2, 2026, with a conference call on November 6, 2026.

SLDB, US83422E2046, Illustration mit AI erstellt.

Solid Biosciences (ISIN US83422E2046) became the subject of fresh analyst coverage after UBS initiated the stock with a Buy rating and a USD 20.00 price target on October 14, 2026, according to Markets Insider. UBS modeled 2035 unadjusted sales of USD 3.2 billion against USD 2.8 billion consensus, a 14.29 percent premium.

Three dated catalysts

On August 6, 2026, Solid Biosciences reported a GAAP net loss of USD 54.8 million for the second quarter, compared with USD 39.48 million a year earlier, according to Markets Insider. On September 16, 2026, RBC began coverage with an Outperform rating and a USD 18.00 target, as reported by MarketScreener. UBS followed on October 14, 2026, with the USD 20.00 target and Buy rating.

What does the target mean?

The UBS target stood 248.43 percent above the USD 5.74 Nasdaq quote last available on October 15, 2026 at 4:00 p.m. ET. The gap reflects the analyst case for SGT-003, Solid Biosciences' lead Duchenne muscular dystrophy program, and the projected sales comparison of USD 3.2 billion versus USD 2.8 billion consensus. Solid Biosciences describes its pipeline as covering rare neuromuscular and cardiac diseases, including SGT-003 and SGT-501, on its Solid Biosciences investor-relations page.

Next reporting dates

Solid Biosciences is estimated to report third-quarter 2026 results on November 2, 2026, before the market opens, with a conference call scheduled for November 6, 2026 at 4:00 p.m. ET, according to MarketBeat.

Nasdaq quote and valuation

The last available Nasdaq quote was USD 5.74 on October 15, 2026 at 4:00 p.m. ET. The stock's 52-week range was USD 3.79 to USD 11.45, while market capitalization stood at USD 615.5 million on that date.